Stem Cell Research May Treat Rare Blood Disorder

    Researchers from UCSD, the Dana-Farber Cancer Institute, the
    Mayo Clinic and TargeGen, a San Diego pharmaceutical company, have joined
    together to perform human clinical trials of a new drug to treat a rare class
    of blood diseases.

    In one year, the partnership has moved from identifying the
    appropriate drug candidate to performing clinical trials in order to fight a
    number of Myeloproliferative disorders that are caused by the same genetic
    mutation and can lead to leukemia. The degenerative blood disorder affects more
    than 100,000 Americans.

    The study was led by Catriona Jamieson, assistant professor
    of medicine and director for stem cell research at the Rebecca and John
    Moores Cancer Center
    ,
    and funded by the California Institute for Regenerative Medicine.

    More to Discover
    Donate to The UCSD Guardian
    $2320
    $500
    Contributed
    Our Goal

    Your donation will support the student journalists at University of California, San Diego. Your contribution will allow us to purchase equipment, keep printing our papers, and cover our annual website hosting costs.

    Donate to The UCSD Guardian
    $2320
    $500
    Contributed
    Our Goal